BioSpace News Archive

Personalis, Inc. announced that, effective on July 15, 2020, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 44,600 shares of its common stock and restricted stock units covering an aggregate of 34,800 shares of its common stock to seven new employees under Personalis’ 2020 Inducement Plan.

A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia.

Berkeley Lights, Inc., a leader in Digital Cell Biology, today announced the pricing of its initial public offering of 8,100,000 shares of common stock at a public offering price of $22.00 per share.

Renalytix AI plc, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces the pricing of its global offering of an aggregate of 11,000,000 new ordinary shares.

Continuing a steady path of growth in the medical device manufacturing industry, Tegra Medical announced today the purchase of an additional building across the street from its Franklin, MA headquarters and an expansion of its space in Hernando, MS.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced that the Company plans to issue its second quarter 2020 financial results after the close of the market on Thursday, July 30, 2020

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.

Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the second quarter ended June 30, 2020, after the market closes on July 28, 2020.

BioConsortia, Inc., innovator of microbial solutions in crop protection, soil fertility, and yield improvement, welcomes Dr. Damian Curtis to the company as Director of Synthetic Biology and Genomics.

BioSig Technologies, Inc., a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that its Board of Directors had adopted a stockholder Rights Agreement.